http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2653473-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_baee372c55802742f9582e25c15ff11a |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-04 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-04 |
filingDate | 2010-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f5b4e3ee32eb183cc944b6c5fb3e109 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_992f998f18c8174a45f3a6840d55a7e1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42012cdf82a0109ee6669df996c596a7 |
publicationDate | 2013-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-2653473-A1 |
titleOfInvention | Fused Aminodihydro-Oxazine Derivatives |
abstract | A compound represented by the general formula:n nor a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C 6-14 aryl group or the like, L is -NR e CO- or the like (wherein R e is a hydrogen atom or the like), Ring B is a C 6-14 aryl group or the like, X is a C 1-3 alkylene group or the like, Y is a single bond or the like, Z is a C 1-3 alkylene group or the like, R 1 and R 2 are each independently a hydrogen atom or the like, and R 3 , R 4 , R 5 and R 6 are independently a hydrogen atom, a halogen atom or the like, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia. |
priorityDate | 2009-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1205.